Skip Nav Destination
Issues
1 April 2013
-
Cover Image
Cover Image
The yeast Rad6 human homologues HHR6A and HHR6B (or Rad6A and Rad6B) encode ubiquitin-conjugating enzymes (or E2) that play a central role in substrate ubiquitination and E3 ligase selection. The ubiquitin-conjugating activity of Rad6 is essential for its function in postreplication DNA repair, damage-induced mutagenesis, and proteolysis. Using virtual screening of ZINC database against a pharmacophore model for consensus, E2-ubiquitin binding sites followed by biological evaluation of virtual hits, two small molecule compounds with a triazine core structure, and possessing Rad6 ubiquitin conjugation inhibitory activity were identified. These small molecules inhibit breast cancer cell proliferation, migration, and colony formation by blocking G2—M progression. For details, see article by Sanders and colleagues on page 373. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Chemical Therapeutics
Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner
Anna R. McCarthy; Marijke C.C. Sachweh; Maureen Higgins; Johanna Campbell; Catherine J. Drummond; Ingeborg M.M. van Leeuwen; Lisa Pirrie; Marcus J.G.W. Ladds; Nicholas J. Westwood; Sonia Laín
Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma
Shylesh Bhaskaran; Kalarikkal V. Dileep; Sathyaseelan S. Deepa; Chittalakkottu Sadasivan; Mitch Klausner; Naveen K. Krishnegowda; Rajeshwar R. Tekmal; John L. VandeBerg; Hareesh B. Nair
Small Molecule Therapeutics
Large Molecule Therapeutics
Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models
Yaming Wu; Yixian Zhang; Maoliang Wang; Qi Li; Zhengxing Qu; Victoria Shi; Patricia Kraft; Steve Kim; Ying Gao; Jenny Pak; Stephen Youngster; Ivan D. Horak; Lee M. Greenberger
Cancer Therapeutics Insights
Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
Pamela Farrell; Lihong Shi; Jennifer Matuszkiewicz; Deepika Balakrishna; Takashi Hoshino; Lilly Zhang; Sarah Elliott; Robyn Fabrey; Bumsup Lee; Petro Halkowycz; BiChing Sang; Seigo Ishino; Toshiyuki Nomura; Mika Teratani; Yoshikazu Ohta; Charles Grimshaw; Bheema Paraselli; Takashi Satou; Ron de Jong
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Zev A. Wainberg; Adrian Anghel; Amy M. Rogers; Amrita J. Desai; Ondrej Kalous; Dylan Conklin; Raul Ayala; Neil A. O'Brien; Cornelia Quadt; Mikhail Akimov; Dennis J. Slamon; Richard S. Finn
Companion Diagnostics & Biomarkers
Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
Angélique Augustin; Jens Lamerz; Hélène Meistermann; Sabrina Golling; Stefan Scheiblich; Johannes C. Hermann; Guillemette Duchateau-Nguyen; Manuel Tzouros; David W. Avila; Hanno Langen; Laurent Essioux; Barbara Klughammer
Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response
María J. García; Laura Paula Saucedo-Cuevas; Iván Muñoz-Repeto; Victoria Fernández; María J. Robles; Samuel Domingo; José Palacios; Miguel Aracil; Antonio Nieto; Juan Carlos Tercero; Javier Benítez
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.